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Antipsychotic medications can have a significant effect on brain function after only 
several days of treatment. It is unclear whether such an acute effect can serve as an early 
predictor for treatment response in schizophrenia. Thirty-two patients with drug-naive, 
first-episode schizophrenia and 32 healthy controls underwent resting-state functional 
magnetic resonance imaging. Patients were treated with olanzapine and were scanned 
at baseline and 1 week of treatment. Healthy controls were scanned once at baseline. 
Symptom severity was assessed within the patient group using the Positive and Negative 
Syndrome Scale (PANSS) at three time points (baseline, 1 week of treatment, and 8 weeks 
of treatment). The fractional amplitude of low frequency fluctuation (fALFF) and support 
vector regression (SVR) methods were used to analyze the data. Compared with the 
control group, the patient group showed increased levels of fALFF in the bilateral putamen 
at baseline. After 1week of olanzapine treatment, the patient group showed decreased 
levels of fALFF in the right putamen relative to those at baseline. The SVR analysis found a 
significantly positive relationship between the reduction in fALFF after 1 week of treatment 
and the improvement in positive symptoms after 8 weeks of treatment (r = 0.431, p = 
0.014). The present study provides evidence that early reduction and normalization of 
fALFF in the right putamen may serve as a predictor for treatment response in patients 
with schizophrenia.
Keywords: schizophrenia, early predictor, olanzapine, fractional amplitude of low frequency fluctuation, pattern 
classification
INTRODUCTION
Antipsychotic medications are the standard treatment for schizophrenia. However, up to 30% of 
patients with schizophrenia respond poorly to current antipsychotic treatment (1). Therefore, it is 
of great clinical value if we can develop a biomarker either before the treatment or during the early 
treatment course to predict clinical outcome. However, previous effort trying to explore clinically 
useful predictors has mostly failed (2, 3, 4).
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Recently, functional magnetic resonance imaging (fMRI) 
provides insights into the underlying pathophysiological 
mechanisms of schizophrenia and antipsychotic effects on brain 
function. Antipsychotic medications are dopamine receptor 
antagonists or partial agonists (5). Antipsychotic treatment 
modulates intrinsic brain activity in the cortical (i.e., the prefrontal 
cortex and anterior cingulate cortex) and subcortical regions (i.e., 
the basal ganglia and amygdala) in patients with schizophrenia, 
which constitute the thalamocortical network (6, 7, 8, 9). Results 
from longitudinal investigations indicate a normalization and a 
concurrent denormalization of intrinsic brain activity related to 
antipsychotic treatment in schizophrenia (2, 3, 4). We have reported 
that olanzapine increases functional connectivity (FC) in the default-
mode network (DMN) and sensorimotor circuits and decreases FC 
in the left superior temporal gyrus (10, 11, 12) in schizophrenia. 
In addition, Lui et al. observed a significant relationship between 
improvement in clinical symptoms and alterations of brain activity 
in drug-naive, first-episode schizophrenia (13). Another study 
suggested that prefrontal lobe dysfunction predicts treatment 
response in drug-naive, first-episode schizophrenia (14).
Although the abovementioned studies provide useful information 
for us to understand antipsychotic treatment effect on brain activity 
in schizophrenia, several important issues in the existing literature 
need to be addressed. First, in most previous studies, patients 
were exposed to different antipsychotic medications. For example, 
risperidone, olanzapine, clozapine, aripiprazole, and sulpiride were 
used in a study with first-episode schizophrenia (13). Different 
antipsychotic medications may have differential effects on brain 
function as reported in positron emission tomography (PET) studies 
(15, 16). Second, chronic patients with a long illness duration were 
recruited in some previous studies (10, 11, 12). The illness duration 
itself may have a neurotoxic effect on brain gray matter (17). Third, 
many previous studies have focused on specified brain regions or 
networks using a region-of-interest (ROI) method (18, 19). It is not 
surprising that different studies reported different findings when 
different ROIs were used. Although the findings are meaningful, the 
ROI method may not include all significant brain regions that are 
related to the core pathological alterations in schizophrenia.
Taking these potentially important confounding factors into 
consideration, the present study was to examine whether acute 
changes in the brain, 1 week after olanzapine treatment, can predict 
clinical response after 8 weeks of olanzapine treatment in drug-
naive, first-episode schizophrenia because antipsychotic drugs may 
have acute effects on brain function after only 1 week of treatment 
when it is in general still too early to observe meaningful clinical 
improvement (20). Fractional amplitude of low frequency fluctuation 
(fALFF) was used to analyze the imaging data in a voxel-wise and 
whole-brain fashion. Support vector regression (SVR) analysis, one 
of pattern classification approaches, was used to predict individual 
level clinical response after 8 weeks of olanzapine treatment.
METHODS
Participants
A total of 68 right-handed participants were recruited, including 
34 patients with drug-naive, first-episode schizophrenia and 34 
healthy controls. Patients were recruited from the Department 
of Psychiatry, the Second Xiangya Hospital of Central South 
University in China, and healthy controls were recruited from 
the local community. Schizophrenia was diagnosed using the 
Structural Clinical Interview for DSM-IV (SCID), patient 
version (21). All participants had more than 6 years of formal 
education and aged from 18 to 50 years old. All participants 
had routine laboratory tests and a physical exam, and met the 
following exclusion criteria: any psychiatric disorders other than 
schizophrenia and any medical disorders. For healthy controls, 
those who have a first-degree relative with psychiatric disorders 
were excluded.
The study was approved by the ethics committee of the Second 
Xiangya Hospital of Central South University, China. Each 
participant provided a written informed consent to participate 
in the study.
Procedure
Clinical symptoms were assessed using the Positive and Negative 
Syndrome Scale (PANSS), which includes the positive symptoms, 
negative symptoms, and general psychopathology subscales (22). 
All patients were treated with olanzapine as clinically appropriate 
and tolerated (week 1: dose range 10–20 mg/day with mean and 
standard deviation 12.19 and 3.09, respectively; week 8: dose 
range 10–30 mg/day with mean and standard deviation 18.59 and 
4.96, respectively). For patients, clinical symptom assessment and 
the imaging scan were performed twice (pre-treatment baseline, 
after 8 weeks of treatment). For healthy controls, the imaging 
scan was performed at baseline.
Data Acquisition and Preprocessing
MRI images were obtained using a 3T MRI scanner (Siemens 
Verio, Erlangen, Germany). The participants were required 
to remain motionless and awake with their eyes closed. Soft 
earplugs and foam pads were used to decrease scanner noise and 
head motion. Resting-state fMRI images were obtained with a 
gradient-echo echo-planar imaging (EPI) sequence using the 
following parameters: repetition time/echo time = 2,000 ms/30 
ms, 33 slices, 64 × 64 matrix, 90° flip angle, 22 cm field of view, 4 
mm slice thickness, no slice gap, and 240 volumes (480 s).
The images were preprocessed in Matlab (R2012b) using 
the DPABI software (V4.1_190725) (23) and SPM8. After 
slice timing and head motion correction, participants with 
over 2 mm maximal translation and 2° maximal rotation 
were excluded. Several covariates, including Friston-24 head 
motion parameters (6 head motion parameters, 6 head motion 
parameters one time point before, and 12 corresponding 
squared items) acquired via rigid body correction (24), signal 
from a ventricular region of interest, and signal from a region 
centered in the white matter, were removed. The global signal 
was not removed as it is still a controversial practice in the 
resting-state fMRI field (25). The data were then normalized 
to conventional EPI template in the Montreal Neurological 
Institute (MNI) space and resampled to 3 × 3 × 3 mm3 voxels. 
Finally, the images were bandpass-filtered (0.01–0.08 Hz) and 
linearly detrended.
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Calculation of fALFF
The analysis procedure for fALFF was performed according to 
the methods described in a previous study (26). First, the time 
course of each voxel was converted to the frequency domain 
without bandpass filtering with a fast Fourier Transform (FFT) 
and the power spectrum was acquired. Then, the square root 
was calculated at each frequency of the power spectrum because 
the power of a given frequency was proportional to the square 
of the amplitude of its frequency component, and the averaged 
square root was obtained across 0.01–0.08 Hz at each voxel. The 
sum of amplitude across 0.01–0.08 Hz was divided by that across 
the whole frequency range. Finally, the fALFF of each voxel was 
divided by the global mean fALFF value within a brain mask for 
standardization purpose (27). This method has been well applied 
in psychiatric disorders, such as schizophrenia (28, 29, 30), major 
depressive disorder (27, 31, 32), somatization disorder (33), and 
healthy subjects (34).
Statistical Analyses
Demographic and clinical data were analyzed using chi-square 
test and two-sample t-test as appropriate.
Group comparisons between patients and healthy controls 
were performed at baseline to identify brain regions with 
abnormal values of fALFF in schizophrenia. For those abnormal 
brain regions, paired-sample t-test was performed within the 
patient group to compare values of fALFF between 1 week after 
olanzapine treatment and baseline. Framewise displacement 
(FD) was calculated for each participant according to the method 
described in a previous study (35). The mean FD, age, gender, 
years of education, and individual dose of olanzapine were used 
as covariates of no interest. The significance level of p value 
was corrected for multiple comparisons based on the Gaussian 
random field (GRF) theory (voxel significance: p < 0.001, cluster 
significance: p < 0.05) using the software REST (36).
Improvement in Clinical Symptoms
We calculated the reduction rate (RR) of the PANSS total scores 
using the following formula.
 RR PANSS PANSS Ptotal_8w total_0 total_8w⋅ = ⋅ ⋅ − ⋅( )⋅ ⋅/ ANSStotal_0
Note: RRtotal_8w refers to the reduction rate of the PANSS total 
score after 8 weeks of treatment. PANSStotal_0 is the PANSS total 
score at baseline, whereas PANSStotal_8w is the PANSS total score 
after 8 weeks of treatment. The RR of each PANSS subscale was 
calculated using a similar formula.
Pattern Classification
Pattern classification was conducted using the LIBSVM software 
(http://www.csie.ntu.edu.tw/~cjlin/libsvm/), including a set 
of machine learning-based algorithms to differentiate two or 
more groups based on high-dimensional data such as functional 
images. In the present study, an SVR was performed using a 
“leave-one-out” procedure and based on the mean fALFF values 
of the identified cluster. The purpose of SVR was to examine 
whether changes of fALFF after 1 week of olanzapine treatment 
can predict improvement in clinical symptoms after 8 weeks 
of treatment as reflected by the RRs of the PANSS total and 
subscale scores.
RESULTS
Characteristics of the Participants
The flowchart of the study participants is shown in Figure 1. 
The imaging scans from three participants (two patients and one 
healthy control) were discarded due to excessive head motion; 
one healthy control withdrew the consent. The final analysis 
included 32 patients and 32 healthy controls. There were no 
significant differences between the two groups in gender, age, 
years of education, and the mean FD value (p’s > 0.20) (Table 1).
Improvement in Clinical Symptoms 
Within the Patient Group After 8 Weeks of 
Treatment
At baseline, the PANSS total score, positive symptoms score, 
negative symptoms score, and general psychopathology score 
were 77.38 ± 5.17/20.00 ± 4.32/20.59 ± 3.46/36.78 ± 3.68, 
respectively (mean ± SD). A significant reduction was found on 
the PANSS total and subscale scores after 8 weeks of treatment 
compared to baseline (p’s < 0.001) (Table 2).
FIGURE 1 | Flowchart of the study participants.
TABLE 1 | Characteristics of the study participants at baseline.
Patients 
(n = 32)
Controls 
(n = 32)
p value
Gender (male/female) 16/16 21/11 0.21
Age (years) 30.94 ± 8.25 31.37 ± 7.84 0.83
Years of education (years) 12.13 ± 3.19 12.03 ± 2.38 0.89
FD (mm) 0.03 ± 0.02 0.03 ± 0.02 0.92
Illness duration (months) 8.91 ± 6.39
Dose of olanzapine at 
week 1 (mg/day)
12.19 ± 3.09
Dose of olanzapine at 
week 8 (mg/day)
18.59 ± 4.96
FD, framewise displacement.
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Baseline Differences in fALFF Between 
Patients and Healthy Controls
At baseline, compared with the control group, the patient group 
showed increased levels of fALFF in the bilateral putamen/
caudate/pallidum, right cerebellum pons, left cerebellum culmen, 
right inferior parietal lobule, left inferior parietal lobule, and left 
superior parietal lobule, and decreased levels of fALFF in the left 
medial frontal gyrus (orbital part), right fusiform gyrus/lingual 
gyrus, left calcarine cortex/precuneus, and left superior occipital 
lobe (Figure 2 and Table 3).
Alterations in fALFF After 1 Week  
of Olanzapine Treatment Within  
the Patient Group
After 1 week of treatment, the patient group showed decreased 
and normalized levels of fALFF in the right putamen relative to 
TABLE 2 | The PANSS scores within the patient group.
PANSS Baseline week 1 week 8 
Mean ± SD Mean ± SD  
(p value)
Mean ± SD  
(p value)
Positive 
symptoms 
scores
20.00 ± 4.32 18.81 ± 4.76  
(p = 0.217)
8.91 ± 1.55  
(p < 0.001)
Negative 
symptoms 
scores
20.59 ± 3.46 20.56 ± 3.45  
(p = 0.967)
8.97 ± 1.84 
 (p < 0.001)
General 
psychopathology 
subscale scores
36.78 ± 3.68 35.13 ± 3.63  
(p = 0.035)
18.63 ± 1.48  
(p < 0.001)
Total scores 77.38 ± 5.17 74.50 ± 5.61 
 (p = 0.017)
36.50 ± 2.97  
(p < 0.001)
PANSS, Positive and Negative Syndrome Scale; p values represent the comparisons 
of the PANSS scores between week 1 or week 8 and baseline.
FIGURE 2 | Baseline differences in fALFF between patients and healthy controls. The figure is presented using the viewer of the REST software. Color bars indicate 
t-values of the group analysis. Red color denotes increased fALFF in the patient group compared to the control group, whereas blue color denotes decreased fALFF 
in the patient group compared to the control group (p < 0.05, corrected by the GRF method). fALFF, fractional amplitude of low frequency fluctuation;  
GRF, Gaussian random field.
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those at baseline (Figure 3 and Table 4). For other brain areas 
with abnormal levels of fALFF at baseline, no significant changes 
were found after 1 week of olanzapine treatment within the 
patient group.
Pattern Classification Results
Since the right putamen was the only brain region that showed 
decreased and normalized fALFF after 1 week of olanzapine 
treatment, the change in levels of fALFF in the right putamen 
at week 1 might be able to predict treatment response at week 8. 
To test this possibility, SVR analysis was conducted. The SVR 
result showed a significantly positive relationship between 
decreased levels of fALFF at week 1 and the improvement in 
positive symptoms at week 8 as measured by the RR of the 
PANSS positive symptoms subscale scores (r  = 0.431, p = 
0.014, Figure 4).
DISCUSSION
To our knowledge, the present study was the first to explore 
an early imaging biomarker to predict antipsychotic treatment 
response in drug-naive, first-episode schizophrenia using a 
combination of fMRI data and pattern classification methods. 
We found that reduced and normalized fALFF in the right 
putamen after 1 week of olanzapine treatment may serve as a 
predictor for improvement in positive symptoms after 8 weeks 
of olanzapine treatment.
Our findings are in line with a previous report (37), which 
observed increased levels of ALFF in the right putamen 
in patients with or without auditory hallucinations in first 
episode schizophrenia. Our findings are also consistent with 
the results from another study that showed that medicated 
patients with schizophrenia had decreased metabolic rates 
in the putamen relative to never-medicated patients (38). 
Further, our findings are consistent with a previous study 
that reported that increased gray matter (GM) volume in the 
right putamen might be a marker to predict antipsychotic 
treatment response in schizophrenia (39). In that study, 
patients with drug-naive, first-episode schizophrenia received 
antipsychotic treatment for 6 weeks. The imaging data were 
analyzed using a tensor-based morphometry method. It 
was found that increased GM volume in the right putamen 
after 6 weeks of treatment was associated with improvement 
in positive symptoms of schizophrenia. Together with 
these studies, the present study  suggests that structural and 
functional changes in putamen  in response to antipsychotic 
treatment might be associated with  clinical outcome in 
patients with schizophrenia.
The putamen, a subcortical node of the striatum, is rich in 
dopamine, a main neurotransmitter in the brain. Dopamine 
plays a key role in complex behavior and cognition in 
TABLE 3 | Baseline differences in fALFF between patients and healthy controls.
Cluster location Peak (MNI) Number of voxels T value
x y z
Bilateral Putamen/Caudate/Pallidum 15 3 12 403 5.8517
Right Cerebellum Pons 12 -36 -39 83 4.0648
Left Cerebellum Culmen -12 -54 -24 41 3.7255
Right Inferior Parietal Lobule 48 -27 33 32 4.5249
Left Inferior Parietal Lobule -48 -45 60 36 4.3778
Left Superior Parietal Lobule -18 -60 72 70 4.2737
Right Fusiform Gyrus/Lingual Gyrus 27 -69 -6 115 -4.2794
Left Calcarine Cortex/Precuneus/
Superior Occipital Lobe
-6 -69 18 174 -4.8369
MNI, Montreal Neurological Institute; fALFF, fractional amplitude of low frequency fluctuation.
FIGURE 3 | Changes in fALFF after 1 week of olanzapine treatment within 
the patient group (the right putamen). The comparisons were limited to 
the brain regions with abnormal levels of fALFF at baseline. The figure 
is presented using the viewer of the REST software. Color bar indicates 
t-values of the group analysis. Blue color denotes decreased fALFF after 1 
week of olanzapine treatment relative to the values at baseline (p < 0.05, 
corrected by the GRF method). fALFF, fractional amplitude of low frequency 
fluctuation; GRF, Gaussian random field.
TABLE 4 | Treatment effect on fALFF after 1 week of olanzapine treatment within 
the patient group.
Cluster 
location
Peak (MNI) Number 
of voxels
T value
x y z
Right Putamen 15 12 3 22 -3.7892
MNI, Montreal Neurological Institute; fALFF, fractional amplitude of low frequency 
fluctuation.
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schizophrenia (40). According to the dopamine hypothesis in 
schizophrenia, excessive dopamine in the striatum (including 
the putamen) is associated with positive symptoms such as 
hallucinations and delusions (41). Antipsychotic medications 
target multiple dopaminergic receptors including D1 and D2 
in the striatum, which might contribute to improvement in 
positive symptoms. Therefore, reduced and normalized fALFF 
in the right putamen, even in the early treatment course, was 
associated with improvement in positive symptoms in the 
present study.
Our study has several novel aspects. First, we identified 
a possible imaging biomarker at 1 week of treatment to 
predict clinical response at 8 weeks of treatment. Clinically, 
it usually takes 6–8 weeks to determine clinical effectiveness 
of antipsychotic treatment. Therefore, establishing an early 
predictor for treatment response is of great clinical value to 
help psychiatrists decide, during the early treatment course, 
whether the patient should stay on the chosen antipsychotic 
medication or switch to a different one. Second, a ROI 
method was commonly used in previous studies; this method 
focuses on selected brain regions but may miss other brain 
regions that are critical to the underlying pathophysiology 
of schizophrenia (19). In contrast, the fALFF analysis, which 
takes a voxel-wise whole-brain approach, was used in our 
study. Third, most previous studies that tried to identify 
predictors for treatment response used univariate statistics, 
which is appropriate for group level prediction (42); in 
contrast, SVR analysis, a pattern classification technique used 
in our study, is a promising tool for individual level prediction 
(43). Fourth, the present study included patients with drug-
naive, first-episode schizophrenia, minimizing several 
important possible confounding factors, such as a long illness 
duration and prior exposure to antipsychotic medication.
The mean age of patients seems older than in typical first-
episode patients, such as patients in our previous study (44). 
Different inclusion criteria on age were used in our two studies. 
The previous study was conducted in Guangxi and included 
participants aged from 16 to 30 years, whereas the present study 
was performed in Changsha and included participants aged from 
18 to 50 years. The typical age range for first episode psychosis is 
16–35 years old. In the present study, most patients fell into this 
age range and only four patients were older than 35 years. Hence, 
the patients in the present study in general still represent usual 
first-episode drug-naive patients with schizophrenia.
The present study has several limitations. First, the 
relatively small sample size may limit the generalizability of 
the results from the present study. Second, all patients were 
treated with olanzapine; the findings from this study may 
not be able to generalize to other antipsychotic medications. 
Third, imaging scans were not done 8 weeks after treatment. 
Therefore, it is unclear whether the changes in fALFF 
observed at week 1 persisted at week 8. Future studies with a 
larger sample size are needed to further examine the clinical 
utility of using acute changes in fALFF in the right putamen 
to predict antipsychotic treatment response in patients with 
schizophrenia.
In conclusion, the present study provides evidence that early 
reduction and normalization of fALFF in the right putamen 
may serve as a predictor for treatment response in patients 
with schizophrenia.
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FIGURE 4 | SVR analysis indicates that decreased levels of fALFF in the right putamen after 1 week of olanzapine treatment may predict improvement in positive 
symptoms after 8 weeks of olanzapine treatment. Left: 3D visualization of SVR results with the best parameters (best c = 22.6274, g = 0.015625) using the grid 
search method. Right: A positive correlation between predicted and actual reduction rates of individual level PANSS positive symptoms subscale scores after 8 
weeks of treatment (r = 0.431, p = 0.014). The predicted reduction rates were calculated based on decreased levels of fALFF in the right putamen after 1 week of 
olanzapine treatment using the LIBSVM software. SVR, support vector regression; MSE, mean square error; fALFF, fractional amplitude of low frequency fluctuation; 
PANSS, the Positive and Negative Syndrome Scale.
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